GSK (GSK) announces that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026. Miels joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- Trump Weekly: President threatens new tariffs, announces TikTok deal
- Trump threatens new tariffs on drugs, kitchen cabinets, trucks: Morning Buzz
- Trump announcement gives big pharma ‘light at end of the tunnel,’ says Jefferies
- Trump to impose 100% tariff on drugs unless manufacturer building U.S. plant
- GlaxoSmithKline (GSK) Bets on Politics and U.S. Pipeline to Reclaim Pharma Prominence